和铂医药(02142.HK)盘中股价大涨5%,引发投资者广泛关注。
消息面上,公司旗下多个创新药品项目已成功与跨国药企达成授权或新公司合作关系,将创新药资产授权出海。分析人士认为,这表明公司在创新药领域的长期增长潜力获市场认可,投资者对公司未来发展前景持乐观预期。
业内人士指出,随着创新药集采政策的持续实施、财政和医保利好政策接连出台、整体行业估值仍处于低位,未来创新药行业仍有较大估值修复空间。和铂医药作为行业龙头,或将成为此轮行业复苏的主要受益者之一。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.